No Data
No Data
Joincare Pharmaceutical Group Industry (600380.SH) will distribute a dividend of 0.18 yuan per share for the year 2023, with a registration date of July 17th.
Joincare Pharmaceutical Group Industry (600380.SH) announced that it will implement annual equity distribution in 2023, with a dividend per share of ...
Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
With its stock down 6.6% over the past month, it is easy to disregard Joincare Pharmaceutical Group IndustryLtd (SHSE:600380). However, stock prices are usually driven by a company's financial perfo
China Approves Joincare's Anti-Asthma Drug
China's medical products administrator approved the drug registration of Joincare Pharmaceutical Group (SHA:600380) for salmeterol xinafoate and fluticasone propionate powder for inhalation, according
Increases to Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) CEO Compensation Might Cool off for Now
Key Insights Joincare Pharmaceutical Group IndustryLtd's Annual General Meeting to take place on 7th of June Salary of CN¥2.60m is part of CEO Xiong Yu's total remuneration Total compensation is 9
China Approves Joincare Unit's Asthma Drug
China approved the drug registration of Joincare Pharmaceutical Group (SHA:600380) subsidiary Shanghai Fangyu Health Pharmaceutical Technology's fluticasone propionate nebulizer suspension. The drug i
Health Source (600380.SH): Fluticasone propionate suspension for atomized inhalation obtained a drug registration certificate
On May 27, Ge Longhui Health Yuan (600380.SH) announced that Shanghai Fangyu Health Pharmaceutical Technology Co., Ltd. (abbreviation: Shanghai Fangyu), a holding subsidiary of the company, has received the “Drug Registration Certificate” approved and issued by the State Drug Administration. This product is an inhaled glucocorticoid (ICS) drug. It has been independently developed by Shanghai Fangyu and is included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue”. Fluticasone propionate is a synthetic trifluorocarbon corticosteroid with anti-inflammatory activity. It has high lipophilicity and receptors
No Data